What drove SLNO's EPS stability in 2024?

Soleno Therapeutics (SLNO) experienced a negative EPS of $4.38 in 2024, which indicates that the company had a net loss for the period. The negative EPS was primarily driven by the significant increase in research and development (R&D) expenses and general and administrative costs. 1. **Increase in R&D Expenses**: Soleno's R&D expenses rose to $30.1 million, up from $6.0 million in the previous year. This increase was primarily due to stock-based compensation and preparation for the commercial launch of their lead product candidate, DCCR. The higher R&D expenses reflect the company's commitment to innovation and development in the biopharmaceutical sector. 2. **Increase in General and Administrative Expenses**: The company's general and administrative expenses also saw a notable increase, reaching $49.2 million, up from $3.3 million in the same period of 2023. This increase was driven by preparations for the product's market entry, including non-cash stock-based compensation. In summary, Soleno Therapeutics' negative EPS in 2024 was primarily driven by the substantial increase in R&D expenses and general and administrative costs, reflecting the company's significant investments in product development and preparation for commercialization. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |SLNO|SLNO.O|Soleno Therapeutics|2024 Q1|32.95454545454546|-0.59|186| |SLNO|SLNO.O|Soleno Therapeutics|2024 Q2|29.62962962962964|-0.57|186| |SLNO|SLNO.O|Soleno Therapeutics|2024 Q3|-92.63157894736844|-1.83|186|